Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Growth Hormone Therapeutic
- Development stage
- Preclinical
- Lead developer
- ASAKE Biotechnology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Growth Hormone Therapeutic is a second-generation biologic candidate under development by ASAKE Biotechnology for the treatment of acromegaly. It functions as a dual receptor antagonist, targeting both the human growth hormone (hGH) receptor and the human prolactin (hPRL) receptor. By blocking these receptors, the therapeutic aims to normalize the pathological signaling associated with growth hormone overproduction. The program is currently in the preclinical stage of development and is designed to offer improved efficacy or safety over first-generation growth hormone receptor antagonists.
- Other names
- Growth Hormone Therapeutic (second-generation)
02
Targets
GHR (Growth hormone receptor)PRLR (Prolactin receptor)
Beyond the preview
Go deeper on Growth Hormone Therapeutic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Growth Hormone Therapeutic.